Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: J Cell Physiol. 2016 Mar 6;231(10):2088–2096. doi: 10.1002/jcp.25336

Figure 3. Pancreatic toxicity of PERK inhibition.

Figure 3

PERK inhibition by either genetic deletion or pharmacological inhibition causes IFN signaling increase in pancreas and accumulation of misfolded insulin, proinsulin and glucose transporters Glut2, leading to hyperglycermia and diabetes. In human, PERK inactivation mutation results in Wlocott-Rallison syndrome, which is characterized with pancreatic degeneration and diabetes.